Format

Send to

Choose Destination
Viruses. 2018 Mar 13;10(3). pii: E126. doi: 10.3390/v10030126.

Development and Testing of a Method for Validating Chemical Inactivation of Ebola Virus.

Author information

1
Department of Virology and Immunology, Texas Biomedical Research Institute, San Antonio, TX 78227, USA. kalfson@txbiomed.org.
2
Department of Virology and Immunology, Texas Biomedical Research Institute, San Antonio, TX 78227, USA. agriffiths@txbiomed.org.

Abstract

Complete inactivation of infectious Ebola virus (EBOV) is required before a sample may be removed from a Biosafety Level 4 laboratory. The United States Federal Select Agent Program regulations require that procedures used to demonstrate chemical inactivation must be validated in-house to confirm complete inactivation. The objective of this study was to develop a method for validating chemical inactivation of EBOV and then demonstrate the effectiveness of several commonly-used inactivation methods. Samples containing infectious EBOV (Zaire ebolavirus) in different matrices were treated, and the sample was diluted to limit the cytopathic effect of the inactivant. The presence of infectious virus was determined by assessing the cytopathic effect in Vero E6 cells. Crucially, this method did not result in a loss of infectivity in control samples, and we were able to detect less than five infectious units of EBOV (Zaire ebolavirus). We found that TRIzol LS reagent and RNA-Bee inactivated EBOV in serum; TRIzol LS reagent inactivated EBOV in clarified cell culture media; TRIzol reagent inactivated EBOV in tissue and infected Vero E6 cells; 10% neutral buffered formalin inactivated EBOV in tissue; and osmium tetroxide vapors inactivated EBOV on transmission electron microscopy grids. The methods described herein are easily performed and can be adapted to validate inactivation of viruses in various matrices and by various chemical methods.

KEYWORDS:

Ebola virus; chemical inactivation; cytopathic effect; limit of detection; viability testing

PMID:
29533988
PMCID:
PMC5869519
DOI:
10.3390/v10030126
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Multidisciplinary Digital Publishing Institute (MDPI) Icon for PubMed Central
Loading ...
Support Center